Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation

Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation

Background: Human cytomegalovirus (HCMV) causes a ubiquitous infection which can pose a significant threat for immunocompromised individuals, such as those undergoing solid organ transplant (SOT). Arguably, the most successful vaccine studied to date is the recombinant glycoprotein-B (gB) with MF59...

Full description

Bibliographic Details
Main Authors: Ilona Baraniak, Ariane C. Gomes, Isabella Sodi, Toby Langstone, Emily Rothwell, Claire Atkinson, Sylvie Pichon, Fabienne Piras-Douce, Paul D. Griffiths, Matthew B. Reeves
Format: Article
Language:English
Published: Elsevier 2019-12-01
Series:EBioMedicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396419307467

Similar Items

Similar Items